MX2009008779A - Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación. - Google Patents

Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación.

Info

Publication number
MX2009008779A
MX2009008779A MX2009008779A MX2009008779A MX2009008779A MX 2009008779 A MX2009008779 A MX 2009008779A MX 2009008779 A MX2009008779 A MX 2009008779A MX 2009008779 A MX2009008779 A MX 2009008779A MX 2009008779 A MX2009008779 A MX 2009008779A
Authority
MX
Mexico
Prior art keywords
pyrazine derivative
pharmaceutical composition
combination
treatment
influenza
Prior art date
Application number
MX2009008779A
Other languages
English (en)
Inventor
Masako Maekawa
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of MX2009008779A publication Critical patent/MX2009008779A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulga una composición farmacéutica que comprende un derivado de pirazina representado por la formula general: [En donde R1 y R2 representan un átomo de hidrogeno o un átomo de halógeno y R3 representa un átomo de hidrogeno o un grupo protector de amino] o una sal del mismo y por lo menos un inhibidor de neuraminidasa. La composición farmacéutica es útil para el tra5tamiento incluyendo el tratamiento o prevención de la influenza. También se divulga un método para usar estos compuestos en combinación. El método es útil para el tratamiento que incluye el tratamiento prevención de la influenza.
MX2009008779A 2007-02-16 2008-02-14 Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación. MX2009008779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007035975 2007-02-16
PCT/JP2008/052425 WO2008099874A1 (ja) 2007-02-16 2008-02-14 ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法

Publications (1)

Publication Number Publication Date
MX2009008779A true MX2009008779A (es) 2009-11-05

Family

ID=39690101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008779A MX2009008779A (es) 2007-02-16 2008-02-14 Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación.

Country Status (21)

Country Link
US (1) US8759354B2 (es)
EP (1) EP2123276B1 (es)
JP (1) JP5255456B2 (es)
KR (1) KR101479083B1 (es)
CN (1) CN101610772B (es)
AU (1) AU2008215397B2 (es)
BR (1) BRPI0807597B8 (es)
CA (1) CA2677905C (es)
CY (1) CY1113435T1 (es)
DK (1) DK2123276T3 (es)
ES (1) ES2396595T3 (es)
HR (1) HRP20130111T1 (es)
IL (1) IL200285A (es)
MX (1) MX2009008779A (es)
NZ (1) NZ578989A (es)
PL (1) PL2123276T3 (es)
PT (1) PT2123276E (es)
RU (1) RU2463051C2 (es)
SI (1) SI2123276T1 (es)
WO (1) WO2008099874A1 (es)
ZA (1) ZA200905536B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117114A1 (en) * 2009-04-09 2010-10-14 Lg Electronics Inc. Display apparatus
KR101745386B1 (ko) * 2010-05-10 2017-06-09 아카데미아 시니카 항-인플루엔자 활성을 가진 자나미비르 포스포네이트 동족체 및 인플루엔자 바이러스의 오셀타미비르 감수성을 확인하는 방법
RS54408B1 (en) 2010-09-30 2016-04-28 Toyama Chemical Co. Ltd. SODIUM SO 6-FLUOR-3-HYDROXY-2-PYRAZINE CARBOXAMIDE
EP2623497B1 (en) 2010-09-30 2016-01-20 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
JP6417568B2 (ja) * 2013-05-14 2018-11-07 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 抗インフルエンザ組成物及び方法
CN104447585B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 吡嗪类化合物及其组合物及用途
CN104447584B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104402833B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447583B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104496918B (zh) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 吡嗪衍生物及其用途
CN104817511B (zh) * 2015-04-27 2017-04-19 济南大学 一种丁烯二酸酐制备法匹拉韦关键中间体的方法
SG10201911957QA (en) * 2015-12-15 2020-02-27 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
US20220096468A1 (en) 2018-12-25 2022-03-31 Fujifilm Toyama Chemical Co., Ltd. Therapeutic agent for RNA viral infection comprising a combination of pyrazine derivative and compound which increases amount of pyrazine derivative ribose triphosphate in cell
JP7449379B2 (ja) 2020-05-27 2024-03-13 富士フイルム富山化学株式会社 ピラジン誘導体とチオプリン誘導体を組み合わせてなるｒｎａウイルス感染症治療剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01197437A (ja) * 1988-01-29 1989-08-09 Dso Pharmachim 抗ウイルス薬
CN1275947C (zh) * 1998-08-20 2006-09-20 富山化学工业株式会社 含氮杂环羧酰胺衍生物或其盐
BR0211900A (pt) * 2001-08-14 2004-08-24 Toyama Chemical Co Ltd Método para inibição do desenvolvimento de vìrus e/ou virucida, análogos de nucleotìdeo de pirazina e de nucleosìdeo de pirazina, precursor do inibidor da polimerase de rna, inibidor da polimerase de rna, método para tratar pacientes infectados por vìrus, e, usos de um análogo de nucleotìdeo de pirazina ou um sal deste e de um análogo de nucleosìdeo de pirazina ou um sal deste
JP2005354833A (ja) * 2004-06-11 2005-12-22 Fujinon Corp アクチュエータ
JP4689989B2 (ja) * 2004-08-27 2011-06-01 オリンパス株式会社 振動波リニアモータ及びそれを用いたレンズ装置
DE102008031715A1 (de) 2008-07-04 2010-01-07 Henkel Ag & Co. Kgaa Haarkonditionierende Mittel mit Imidazolinen

Also Published As

Publication number Publication date
EP2123276B1 (en) 2012-11-28
CY1113435T1 (el) 2016-06-22
PL2123276T3 (pl) 2013-04-30
IL200285A0 (en) 2010-04-29
WO2008099874A1 (ja) 2008-08-21
KR20090121289A (ko) 2009-11-25
DK2123276T3 (da) 2013-01-02
KR101479083B1 (ko) 2015-01-07
NZ578989A (en) 2011-07-29
ES2396595T3 (es) 2013-02-22
EP2123276A4 (en) 2011-05-18
BRPI0807597B8 (pt) 2021-05-25
CN101610772A (zh) 2009-12-23
IL200285A (en) 2014-06-30
SI2123276T1 (sl) 2013-03-29
AU2008215397B2 (en) 2012-09-06
US20100087447A1 (en) 2010-04-08
HRP20130111T1 (hr) 2013-02-28
AU2008215397A1 (en) 2008-08-21
JPWO2008099874A1 (ja) 2010-05-27
CA2677905C (en) 2015-03-24
JP5255456B2 (ja) 2013-08-07
EP2123276A1 (en) 2009-11-25
PT2123276E (pt) 2013-01-16
US8759354B2 (en) 2014-06-24
CN101610772B (zh) 2013-01-16
BRPI0807597A2 (pt) 2014-05-06
CA2677905A1 (en) 2008-08-21
ZA200905536B (en) 2010-10-27
RU2009134516A (ru) 2011-03-27
RU2463051C2 (ru) 2012-10-10
BRPI0807597B1 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
MX2009008779A (es) Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación.
TW200833675A (en) Nicotinamide derivatives
HK1121440A1 (en) Biphenyl derivatives and their use in treating hepatitis c
UA87250C2 (ru) Применение соединений пиперазина как гербицидов, средство, способ его получения и способ борьбы с нежелательным ростом растительности, соединения пиперазина, способ их получения (варианты) и промежуточные соединения
UA99908C2 (ru) Пиридопиразиновые производные, способ борьбы с растениями, гербицидные композиции
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MY148634A (en) Pyridazinone derivatives
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2012006026A (es) Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
EA201170094A1 (ru) Производные замещенного пиримидо[2,1-а]изохинолин-4-она
WO2008003854A3 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
TW200719889A (en) Amino acid derivatives
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24

Legal Events

Date Code Title Description
FG Grant or registration